{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:36:18Z","timestamp":1760783778600},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T00:00:00Z","timestamp":1391731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.2","type":"journal-article","created":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T14:22:11Z","timestamp":1391782931000},"page":"e180-e180","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A novel strategy inducing autophagic cell death in Burkitt's lymphoma cells with anti-CD19-targeted liposomal rapamycin"],"prefix":"10.1038","volume":"4","author":[{"given":"K","family":"Ono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Iyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Tatekoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kamihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Miyanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kobune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,7]]},"reference":[{"key":"BFbcj20142_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","volume":"379","author":"EM Molyneux","year":"2012","unstructured":"Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G et al. Burkitt's lymphoma. Lancet 2012; 379: 1234\u20131244.","journal-title":"Lancet"},{"key":"BFbcj20142_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1158\/1535-7163.MCT-10-0833","volume":"10","author":"O Cen","year":"2011","unstructured":"Cen O, Longnecker R . Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma. Mol Cancer Ther 2011; 10: 679\u2013686.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj20142_CR3","first-page":"4472","volume":"63","author":"RR Nepomuceno","year":"2003","unstructured":"Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM . Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472\u20134480.","journal-title":"Cancer Res"},{"key":"BFbcj20142_CR4","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","volume":"25","author":"JB Easton","year":"2006","unstructured":"Easton JB, Houghton PJ . mTOR and cancer therapy. Oncogene 2006; 25: 6436\u20136446.","journal-title":"Oncogene"},{"key":"BFbcj20142_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00005-012-0205-y","volume":"61","author":"W Chaabane","year":"2013","unstructured":"Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz) 2013; 61: 43\u201358.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"1","key":"BFbcj20142_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1182\/asheducation-2008.1.341","volume":"2008","author":"A. S. Perkins","year":"2008","unstructured":"Perkins AS, Friedberg JW . Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program 2008, 341\u2013348, (doi:10.1182\/asheducation-2008.1.341).","journal-title":"Hematology"},{"key":"BFbcj20142_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/1078-0432.CCR-03-0041","volume":"10","author":"P Sapra","year":"2004","unstructured":"Sapra P, Moase EH, Ma J, Allen TM . Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res 2004; 10: 1100\u20131111.","journal-title":"Clin Cancer Res"},{"key":"BFbcj20142_CR8","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-04-2517","volume":"11","author":"TM Allen","year":"2005","unstructured":"Allen TM, Mumbengegwi DR, Charrois GJ . Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005; 11: 3567\u20133573.","journal-title":"Clin Cancer Res"},{"key":"BFbcj20142_CR9","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2004-02-0588","volume":"104","author":"M Harata","year":"2004","unstructured":"Harata M, Soda Y, Tani K, Ooi J, Takizawa T, Chen M et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 2004; 104: 1442\u20131449.","journal-title":"Blood"},{"key":"BFbcj20142_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0005-2736(95)00283-9","volume":"1280","author":"N Oku","year":"1996","unstructured":"Oku N, Tokudome Y, Namba Y, Saito N, Endo M, Hasegawa Y et al. Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. Biochim Biophys Acta 1996; 1280: 149\u2013154.","journal-title":"Biochim Biophys Acta"},{"key":"BFbcj20142_CR11","doi-asserted-by":"publisher","first-page":"e39545","DOI":"10.1371\/journal.pone.0039545","volume":"7","author":"M Yoshida","year":"2012","unstructured":"Yoshida M, Takimoto R, Murase K, Sato Y, Hirakawa M, Tamura F et al. Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach. PLoS One 2012; 7: e39545.","journal-title":"PLoS One"},{"key":"BFbcj20142_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.bbrc.2006.12.060","volume":"353","author":"M Hirai","year":"2007","unstructured":"Hirai M, Minematsu H, Kondo N, Oie K, Igarashi K, Yamazaki N . Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem Biophys Res Commun 2007; 353: 553\u2013558.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFbcj20142_CR13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cmmi.367","volume":"5","author":"M Hirai","year":"2010","unstructured":"Hirai M, Hiramatsu Y, Iwashita S, Otani T, Chen L, Li YG et al. E-selectin targeting to visualize tumors in vivo. Contrast Media Mol Imaging 2010; 5: 70\u201377.","journal-title":"Contrast Media Mol Imaging"},{"key":"BFbcj20142_CR14","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/clinchem\/47.7.1316","volume":"47","author":"DC French","year":"2001","unstructured":"French DC, Saltzgueber M, Hicks DR, Cowper AL, Holt DW . HPLC assay with ultraviolet detection for therapeutic drug monitoring of sirolimus. Clin Chem 2001; 47: 1316\u20131319.","journal-title":"Clin Chem"},{"key":"BFbcj20142_CR15","first-page":"7190","volume":"62","author":"P Sapra","year":"2002","unstructured":"Sapra P, Allen TM . Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002; 62: 7190\u20137194.","journal-title":"Cancer Res"},{"key":"BFbcj20142_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1006\/bbrc.1996.5898","volume":"230","author":"I M\u00fcller","year":"1997","unstructured":"M\u00fcller I, Jenner A, Bruchelt G, Niethammer D, Halliwell B . Effect of concentration on the cytotoxic mechanism of doxorubicin-apoptosis and oxidative DNA damage. Biochem Biophys Res Commun 1997; 230: 254\u2013257.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFbcj20142_CR17","first-page":"885","volume":"53","author":"T Mukherjee","year":"2005","unstructured":"Mukherjee T, Shah BV . Sirolimus: a new immunosuppressant. J Assoc Physicians India. 2005; 53: 885\u2013890.","journal-title":"J Assoc Physicians India."},{"key":"BFbcj20142_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.7150\/thno.4949","volume":"2","author":"Y Nie","year":"2012","unstructured":"Nie Y, Ji L, Ding H, Xie L, Li L, He B et al. Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics 2012; 2: 1092\u20131103.","journal-title":"Theranostics"},{"issue":"Suppl 1","key":"BFbcj20142_CR19","first-page":"5","volume":"5","author":"CA Portell","year":"2013","unstructured":"Portell CA, Wenzell CM, Advani AS . Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 2013; 5 (Suppl 1): 5\u201311.","journal-title":"Clin Pharmacol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bcj20142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bcj20142","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj20142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T02:33:10Z","timestamp":1716517990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj20142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,7]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2]]}},"alternative-id":["BFbcj20142"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,7]]},"assertion":[{"value":"18 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}